TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Trial Details

NCT ID

NCT07190300

Phase

PHASE1 / PHASE2

Sponsor

Novartis Pharmaceuticals

Status

RECRUITING

Cancer Type

Hormone-Sensitive Prostate Cancer

Interventions

• Tulmimetostat
• Darolutamide
• Abiraterone

Locations (sample)

• Birmingham, Alabama, United States|33.52066,-86.80249
• Iowa City, Iowa, United States|41.66113,-91.53017
• Westwood, Kansas, United States|39.04056,-94.6169
• Wichita, Kansas, United States|37.69224,-97.33754
• Durham, North Carolina, United States|35.99403,-78.89862

Key Eligibility Criteria

• Adult men ≥ 18 years old with de novo or recurrent mHSPC (without neuroendocrine or small cell features). The tumor lesion(s) may be located in the…
• Participants must have castrate levels of testosterone, i.e., ≤ 50 ng/dL (≤ 1.7 nM).
• Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
• Adequate bone marrow and organ function

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.